Lonza has completed the acquisition of PharmaCell B.V., a Netherlands-based cell and gene contract manufacturer.

PharmaCell has core expertise in autologous cell and gene therapy manufacturing, which includes experience with two commercial advanced therapy medicinal products. Autologous therapies use a patient’s own cells.

PharmaCell was established in 2005. PharmaCell has more than 6,000 square meters of GMP cleanrooms, quality control, and other support spaces.

Source: Lonza